About
Therapeutic DNA Vaccine
Areas of Focus
Categories
VaccineGene Therapy, RNA & Peptide TherapyNorway
Team (3)
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
272
By Phase
PHASE2: 2PHASE1/PHASE2: 4PHASE1: 1
By Status
COMPLETED: 5WITHDRAWN: 1RECRUITING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06099418Lead Sponsor
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
PHASE2Withdrawn
Started: Apr 18, 2024 · Completed: May 31, 2028
NCT06016920Lead Sponsor
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
PHASE1/PHASE2Recruiting
51 participants
Started: Dec 19, 2023 · Completed: Jan 31, 2028
NCT05018273Lead Sponsor
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
PHASE1Completed
26 participants
Started: Dec 21, 2021 · Completed: Oct 9, 2024
NCT05069623Lead Sponsor
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
PHASE1/PHASE2Completed
68 participants
Started: Nov 1, 2021 · Completed: May 30, 2023
NCT04405349Lead Sponsor
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
PHASE2Completed
52 participants
Started: Jul 1, 2020 · Completed: Nov 24, 2023
Locations (1)
Headquarters
Oslo, Norway
Map
Loading map...